We have enough people with high cholesterol and now there’s a treatment for those who have a genetic condition that promotes high bad cholesterol and this has a big warning for potential liver damage. This is interesting as I would think that any drug in the statin area would do the trick; however this seems like it is “personalized” to take care of the inherited disease and react differently than a molecular only drug. BD
NEW YORK (AP) — Federal regulators have approved Aegerion Pharmaceuticals' treatment for a rare inherited disease that causes extremely high levels of bad cholesterol, the company said Monday.
The company's shares have been hitting annual highs but declined in early trading after the Food and Drug Administration approval of Juxtapid, Aegerion's first drug, was announced.
0 comments :
Post a Comment